[12] Patent
[11] Patent No.:GC0011375  
[45] Date of Publishing the Grant of the Patent: 31/Jul /2020                72/2020  
Number of the Decision to Grant the Patent:2020/171411
Date of the Decision to Grant the Patent:28/Jul/2020

[21] Application No.:GC 2014-27112

[22] Filing Date:6/5/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
FR
7/5/2013
1354204

[72] Inventors:1- GODFRIN Yann،2- BOURGEAUX Vanessa،3- BAILLY Jérôme

[73] Owner: ERYTECH PHARMA, 60 avenue Rockefeller, LYON, F-69008, France

[74] Agent: Abu-Gazaleh Intellectual Property L.L.C

  

 

  

[51]IPC:
Int. Cl.: A61K 9/50 (2006.01)

[56] Cited Documents:

-US 2011/014171 A1 (BOURGEAUX VANESSA [FR]
ET AL) 20 January 2011
-MORAND 0 ET AL: Transport of fatty acids
across the membrane of human erythrocyte
ghosts,
BIOCHIMICA ET BIOPHYSICA ACTA - LIPIDS AND
LIPID METABOLISM, ELSEVIER SCIENCE BV.
AMSTERDAM, NL,
vol. 835, no. 1, 14 June 1985
-US 4 389 209 A (DELOACH JOHN R ET AL)
21 June 1983
-ROSSI LUIGIA ET AL: Macrophage depletion
induced by clodronate-loaded
erythrocytes ,
JOURNAL OF DRUG TARGETING, HARWOOD
ACADEMIC PUBLISHERS GMBH, DE,
vol. 13, no. 2,
1 February 2005
 
Examiner: PH. Mohammad S. AlMousa

[54] METHOD FOR STABILISING SUSPENSIONS OF RED BLOOD CELLS ENCAPSULATING AN ACTIVE INGREDIENT, THE SUSPENSIONS OBTAINED
[57] Abstract: A method for obtaining a stabilised suspension of red blood cells encapsulating an active ingredient, from resealed RBCs incorporating the active ingredient, the method comprising the incubation of the resealed RBCs in an incubation solution at an osmolality of no less than 280 mOsmol/kg, for a time of 30 minutes or more, the incubation solution being a solution that does not contain an agent which is denaturating for the RBC membrane, the liquid medium is then removed from the incubated suspension and the RBCs obtained are placed in suspension in a solution allowing the injection of the suspension in a patient. The suspensions obtained are particularly characterized by an extracellular haemoglobin level maintained at 0.5 or lower, in particular 0.2 g/dl or lower and/or a haemolysis rate maintained at 2 or less, in particular 1 % or less, at 72 h after placing in suspension in a preservation solution and at a temperature of between 2 and 8 °C.
No. of claims: 20     No. of figures: 1


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.